Skip to content
ppharmaranks
Menu
Class IIOngoing

Lidocaine HCL Injection recall

FDA recall D-0594-2024 · initiated Jul 3, 2024

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jul 17, 2024How we research

TAILSTORM HEALTH INC recalled Lidocaine HCL Injection in Jul 2024 — an FDA Class II recall (D-0594-2024) because Subpotent Drug: reduced efficacy for epinephrine.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Subpotent Drug: reduced efficacy for epinephrine

Wrong strength, or it did not keep

The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot Number: 2311003, Expiration Date: 11/13/2024

Quantity recalled: 12,525 10 mL vials

Details

Product
Lidocaine HCL Injection, USP 2% 200mg/10mL (20mg/mL) and EPINEPHRINE HCl 1:200,000, 10 ml Single Dose Vial, Rx only, Compounded drug by Medivant Healthcare, 158 S Kyrene Rd, Chandler, AZ 85226, NDC 81483-0038-0, UPC 3 81483 00380 2
Recalling company
TAILSTORM HEALTH INC
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Jul 3, 2024
FDA report date
Jul 17, 2024
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Lidocaine HCL Injection recalled?
TAILSTORM HEALTH INC recalled Lidocaine HCL Injection in Jul 2024 — an FDA Class II recall (D-0594-2024) because Subpotent Drug: reduced efficacy for epinephrine. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Lidocaine HCL Injection recalled?
Per the FDA enforcement record, the reason for recall D-0594-2024 was: Subpotent Drug: reduced efficacy for epinephrine
Is a recalled Lidocaine HCL Injection dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Lidocaine HCL Injection are affected?
Distributed: Nationwide in the USA. The recall covers these lots — Lot Number: 2311003, Expiration Date: 11/13/2024. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0594-2024.

Source: openFDA Drug Enforcement record D-0594-2024

← All drug recalls